Precigen(PGEN)

Search documents
Precigen(PGEN) - 2019 Q3 - Quarterly Report
2019-11-12 12:55
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 INTREXON CORPORATION (Exact name of registrant as specified in its charter) Virginia 26-0084895 (I.R.S. Empl ...
Precigen(PGEN) - 2019 Q2 - Earnings Call Presentation
2019-08-09 22:29
Intrexon Second Quarter 2019 Business Update August 2019 Forward Looking Statements Safe Harbor Statement Some of the statements made in this presentation are forward-looking statements that involve a number of risks and uncertainties and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon Intrexon's current expectations and projections about future events and generally relate to Intrexon's plans, objectives ...
Precigen(PGEN) - 2019 Q2 - Quarterly Report
2019-08-09 15:45
FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 INTREXON CORPORATION (Exact name of registrant as specified in its charter) Virginia 26-0084895 (I.R.S. Employer ...
Precigen(PGEN) - 2019 Q2 - Earnings Call Transcript
2019-08-09 02:09
Financial Data and Key Metrics Changes - Second quarter revenues were $36 million, a decrease of $9.3 million from the prior year, while year-to-date revenues were $59.3 million, down $25.6 million from the previous year [21] - Total operating expenses for the quarter were $73.4 million, reflecting a 23% decrease year-over-year, and year-to-date operating expenses were $155.4 million, down 17% from the prior year [22] - The company ended the second quarter with a cash balance of $125.8 million and expects to maintain the same cash balance by year-end as of April 3, 2019 [22] Business Line Data and Key Metrics Changes - Precigen is advancing its clinical and preclinical portfolio, including the UltraCAR-T therapeutic platform, with ongoing trials for PRGN-3006 and PRGN-3005 [4][5] - The majority-owned subsidiary Triple-Gene is evaluating INXN-4001 for heart failure, with dosing completed in the first cohort of patients [7][8] - ActoBio Therapeutics is progressing with AG019 for type 1 diabetes, having initiated enrollment for the next patient cohorts [9] Market Data and Key Metrics Changes - Okanagan Specialty Fruits has planted 955,000 new Arctic Apple trees, expecting a five-fold increase in production compared to 2018 [12] - Oxitec's pilot project in Brazil demonstrated an average of 89% peak suppression of Aedes aegypti mosquito populations, indicating strong performance in controlling mosquito-borne diseases [14][15] Company Strategy and Development Direction - The company is focusing on becoming a more strategic healthcare company, with Precigen identified as the top priority [26] - Intrexon is pursuing several transactions, including the sale of Exemplar Genetics and Trans Ova Genetics, to streamline operations and reduce costs [19][20] - The company has decided not to pursue the full initial target of $70 million in operating cost reductions, opting instead to focus on maintaining cash balance [18][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the company's objectives for the year and emphasized the importance of shareholder value [47] - The company is committed to enabling enterprises and believes that its Methane Bioconversion Platform has significant potential despite the decision to transfer it to a new entity [25][28] Other Important Information - The company has partnered with Surterra Wellness for cannabinoid production, utilizing its proprietary yeast fermentation platform [11] - Oxitec has submitted an Experimental Use Permit to the EPA for its second-generation mosquito technology, aiming for a U.S.-based pilot project in 2020 [16] Q&A Session Summary Question: Details on the Methanotroph platform ownership and costs - Management indicated that they aim to secure maximum upside for shareholders while eliminating the need for Intrexon to fund the program further [25] Question: Highlights of PRGN-5001 data - Management deferred detailed data discussion to a future call, expressing excitement about ongoing developments [29] Question: Impact of Arctic apple production increase on revenue - Management stated it is too early to quantify revenue impact but expects to secure purchase orders due to increased supply [31] Question: Status of Trans Ova sale - Management confirmed plans to close the transaction by the fourth quarter, emphasizing the cyclical nature of the field [33][35] Question: Operating expense cuts and focus areas - Management refrained from quantifying specific cuts but reiterated confidence in maintaining cash balance through cost reductions [36] Question: Upcoming healthcare milestones - Management referred to their health-related deck for upcoming milestones, including data readouts for various trials [40] Question: Cost and commercialization of mosquito technology - Management indicated ongoing discussions with potential partners and emphasized the potential for lower production costs [42] Question: Shareholder sentiment on selling revenue-generating assets - Management reported strong support from shareholders for the strategic focus on healthcare, despite selling revenue-generating assets [44]
Precigen(PGEN) - 2019 Q1 - Quarterly Report
2019-05-09 20:52
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 INTREXON CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of inco ...
Precigen(PGEN) - 2018 Q4 - Annual Report
2019-03-01 12:31
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 20374 Seneca Meadows Parkway Germantown, Maryland 20876 (Address of principal executive offices) (Zip Code) FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-36042 INTREXON ...
Precigen(PGEN) - 2018 Q4 - Earnings Call Transcript
2019-03-01 04:03
Intrexon Corp (XON) Q4 2018 Earnings Conference Call February 28, 2019 5:30 PM ET Company Participants Steven Harasym - VP of IR Joel Liffmann - SVP of Finance Bob Walsh - SVP of Energy and Fine Chemicals Nir Nimrodi - Chief Business Officer Thomas Bostick - COO R.J. Kirk - CEO Conference Call Participants Jason Butler - JMP securities Derik De Bruin - Bank of America Operator Good day everyone, and welcome to the Intrexon Fourth Quarter 2018 Financial Results Conference Call. [Operator Instructions] I woul ...
Intrexon (XON) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
2019-01-10 14:34
| --- | --- | --- | --- | --- | --- | |--------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | Precigen Company Update | | | | | | | Helen Sabzevari, PhD President, Precigen | | | | | | | 9 January 2019 JP Morgan 37th Annual Healthcare Conference | | | | | | | | | | | | | | | | | | | | Forward-looking statements Precigen, Inc. is a subsidiary of Intrexon Corporation (Nasdaq: XON). Some of the statements made in this ...